Source comparison
IGF-1 LR3 vs MK-677: Research Application Comparison
Mechanism of Action Direct IGF-1 receptor agonist—bypasses GH/hepatic synthesis entirely Ghrelin mimetic → stimulates pituitary GH release → hepatic IGF-1 conversion IGF-1 LR3 isolates terminal receptor signaling; MK-677 tests the full endocrine cascade Route
This comparison does not assign a generated winner or score.
- Mechanism of Action
- Direct IGF-1 receptor agonist—bypasses GH/hepatic synthesis entirely
- Ghrelin mimetic → stimulates pituitary GH release → hepatic IGF-1 conversion
- IGF-1 LR3 isolates terminal receptor signaling; MK-677 tests the full endocrine cascade
- Route of Administration
- Subcutaneous or intramuscular injection (reconstituted peptide)
- Oral capsule or powder (small molecule)
- MK-677 has higher subject compliance; IGF-1 LR3 requires injection technique and cold storage
- Half-Life
- 20–30 hours
- 24 hours
- Both allow once-daily administration, but IGF-1 LR3 can be split into twice-daily doses for sustained receptor exposure
- Typical Dosing Range
- 20–100 mcg per injection, 1–2× daily
- 10–25 mg once daily
- IGF-1 LR3 doses are measured in micrograms (sub-milligram); MK-677 in milligrams—not directly comparable
- Systemic Hormone Impact
- Raises free IGF-1 only; no effect on GH, cortisol, testosterone, or thyroid
- Elevates both GH and IGF-1; secondary appetite increase and mild insulin resistance at high doses
- IGF-1 LR3 is single-axis; MK-677 affects multiple endocrine pathways and metabolic parameters
- Storage Requirements
- Lyophilized powder at −20°C; reconstituted solution at 2–8°C; 28-day stability post-mixing
- Room temperature stable in capsule or powder form
- Cold-chain failure renders IGF-1 LR3 inactive; MK-677 has no special storage constraints
- Primary Research Context
- Localized tissue growth studies, receptor kinetics, GH-independent IGF-1 signaling
- GH secretagogue research, appetite regulation, age-related GH decline models
- Choose IGF-1 LR3 to study direct receptor effects; choose MK-677 to study endocrine axis responsiveness